EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment

Amel Imene Hadj Bouzid, Stephanie Bui, Ilyes Benlala, Patrick Berger, Antoine Hutt, Renan Liberge, Paul Habert, Jean-Yves Gaubert, Marie Baque-Juston, Baptiste Morel, Gilbert Ferretti, Baudouin Denis de Senneville und 3 weitere

European Radiology · 2024

DOI: 10.1007/s00330-024-11019-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Radiology, 2024. Verfasst von Amel Imene Hadj Bouzid und 14 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Bordeaux, INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, F-33600, Pessac, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Tomography, X-Ray Computed, Artificial Intelligence. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Holistic segmentation of CT structural alterations with 3D deep learning has recently been described in cystic fibrosis (CF), allowing the measurement of normalized volumes of airway abnormalities (NOVAA-CT) as an automated quantitative outcome. Clinical validations are needed, including longitudinal and multicenter evaluations. MATERIALS AND METHODS: The validation study was retrospective between 2010 and 2023. CF patients undergoing Elexacaftor/Tezacaftor/Ivacaftor (ETI) or corticosteroids for allergic broncho-pulmonary aspergillosis (ABPA) composed the monocenter ETI and ABPA groups, respectively. Patients from six geographically distinct institutions composed a multicenter external group. All patients had completed CT and pulmonary function test (PFT), with a second assessment at 1 year in case of ETI or ABPA treatment. NOVAA-CT quantified bronchiectasis, peribronchial thickening, bronchial mucus, bronchiolar mucus, collapse/consolidation, and their overall total abnormal volume (TAV). Two observers evaluated the visual Bhalla score. RESULTS: A total of 139 CF patients (median age, 15 years [interquartile range: 13-25]) were evaluated. All correlations between NOVAA-CT to both PFT and Bhalla score were significant in the ETI (n = 60), ABPA (n = 20), and External groups (n = 59), such as the normalized TAV (ρ ≥ 0.76; p 0.99. CONCLUSION: NOVAA-CT automated scoring demonstrates validity, reliability and responsiveness for monitoring CF severity over an entire lung and quantifies therapeutic effects on lung structure at CT, such as the volumetric reversibility of airway abnormalities with ETI. CLINICAL RELEVANCE STATEMENT: Normalized volume of airway abnormalities at CT automated 3D outcome enables objective, reproducible, and holistic monitoring of cystic fibrosis severity over an entire lung for management and endpoints during therapeutic trials. KEY POINTS: Visual scoring methods lack sensitivity and reproducibility to assess longitudinal bronchial changes in cystic fibrosis (CF). AI-driven volumetric CT scoring correlates longitudinally to disease severity and reliably improves with Elexacaftor/Tezacaftor/Ivacaftor or corticosteroid treatments. AI-driven volumetric CT scoring enables reproducible monitoring of lung disease severity in CF and quantifies longitudinal structural therapeutic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisTomography, X-Ray ComputedArtificial IntelligenceHumansMaleFemaleAdolescentRetrospective StudiesYoung AdultAdultLongitudinal StudiesChildAspergillosis, Allergic BronchopulmonaryRespiratory Function TestsLung

Stichwörter der Autor:innen

AirwaysArtificial intelligenceCTCystic fibrosisDeep learning

Autor:innen und Institutionen

  • Univ. Bordeaux, INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, F-33600, Pessac, France.
  • CHU Bordeaux, Service d'Imagerie Thoracique et Cardiovasculaire, Service des Maladies Respiratoires, Service d'Exploration Fonctionnelle Respiratoire, Paediatric Cystic Fibrosis Reference Center (CRCM), CIC 1401, F-3360…
  • INSERM, U1045, Centre de Recherche Cardio-Thoracique de Bordeaux, CIC 1401, F-33600, Pessac, France.
  • Department of Thoracic Imaging, Heart & Lung Institute, Lille, Cedex, France.
  • Department of Radiology, CHU Nantes, F-44000, Nantes, France.
  • Imaging Department, Hopital La Timone, APHM, Aix Marseille University, Marseille, France.

Zitieren

APA

Hadj Bouzid, A. I., Bui, S., Benlala, I., Berger, P., Hutt, A., Liberge, R., Habert, P., Gaubert, J. Y., Baque-Juston, M., Morel, B., Ferretti, G., Denis de Senneville, B., Laurent, F., Macey, J., & Dournes, G. (2024). Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment. European Radiology. https://doi.org/10.1007/s00330-024-11019-5

Vancouver

Hadj Bouzid AI, Bui S, Benlala I, Berger P, Hutt A, Liberge R, et al. Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment. European Radiology. 2024. doi:10.1007/s00330-024-11019-5

BibTeX
@article{HadjBouzid2024,
  author = {Hadj Bouzid, Amel Imene and Bui, Stephanie and Benlala, Ilyes and Berger, Patrick and Hutt, Antoine and Liberge, Renan and Habert, Paul and Gaubert, Jean-Yves and Baque-Juston, Marie and Morel, Baptiste and Ferretti, Gilbert and Denis de Senneville, Baudouin and Laurent, François and Macey, Julie and Dournes, Gaël},
  title = {Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-11019-5}
}
Kostenlos starten →